Innovent Biologics, Inc. | Fifty 1 Labs, Inc.

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/bb/aa/17/bbaa1773-ecf8-3f1f-498d-ade794a0be21/mza_12437820159870680474.jpg/600x600bb.jpg

Stock Day Media

1488 episodes

8 months ago

Stock Day Media is the top source for Penny and Micro-Cap news in America. Our Mission is to provide transparency to publicly traded companies and inform the investors directly. Our reach in the stock market community gives Stock Day the ability to find new potential investors that are seeking unique and lucrative opportunities.

All content for Stock Day Media is the property of Stock Day Media and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Innovent Biologics, Inc. | Fifty 1 Labs, Inc.

Stock Day Media

1 year ago

Innovent Biologics, Inc. | Fifty 1 Labs, Inc.

Innovent Biologics, Inc. (HKEX: 01801), a world-class biopharmaceutical company announced that clinical data of IBI363 (first-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein) in advanced solid tumors are presented at the 2024 ESMO Virtual Plenary.

Fifty 1 Labs, Inc. (OTCPK: CAFI), a holding company that operates in the sports supplement, fitness equipment, and health and wellness industries is pleased to provide an update to its shareholders regarding recent strategic initiatives and significant developments within the company. Over the past several months, Fifty 1 Labs has been diligently working behind the scenes to position itself for sustained long-term success and robust growth.

For more information, please visit StockDayMedia.com